Company profile
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome,
- CEO
- Mr. Vincent J. Angotti
- Headquarters
- San Mateo, CA, United States
- Employees
- 12
- IPO date
- Feb 11, 2011
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic